Stockscreener 앱 받기
2.50
26.90%
0.53
시간 외 거래:
2.58
0.08
+3.20%
Inflarx Nv 주식(IFRX)의 최신 뉴스
[424B5] InflaRx N.V. Prospectus Supplement (Debt Securities) - Stock Titan
InflaRx advances izicopan development for life-threatening kidney diseases including ANCA-associated vasculitis. - Pluang
InflaRx Q1 2026 earnings preview - MSN
MSN Money - MSN
InflaRx stock surges on AAV drug development plan By Investing.com - Investing.com South Africa
InflaRx stock surges on AAV drug development plan - Investing.com
InflaRx prices $150M offering of ordinary shares - MSN
InflaRx prices $150M stock sale to fund pipeline and working capital - Stock Titan
InflaRx prices $150 million share offering at $2 per share - Investing.com
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029 - TipRanks
InflaRx to develop izicopan for kidney disease treatment By Investing.com - Investing.com Australia
InflaRx (Nasdaq: IFRX) details izicopan kidney strategy and funding through 2029 - Stock Titan
InflaRx Files Q1 2026 Financials with SEC via Form 6-K - TipRanks
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares - ChartMill
Funded through 2029, InflaRx expands izicopan into kidney diseases - Stock Titan
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases - ChartMill
InflaRx (NASDAQ: IFRX) cuts Q1 loss but flags going concern risk - Stock Titan
Top 5 Hot Penny Stocks to Buy Now - Insider Monkey
InflaRx NV expected to post a loss of 14 cents a shareEarnings Preview - TradingView
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study - TipRanks
Low reactive metabolite data support InflaRx (IFRX) oral C5aR1 drug - Stock Titan
InflaRx reports preclinical data on izicopan metabolite formation By Investing.com - Investing.com Australia
In liver lab tests, izicopan showed over 100-fold lower reactive conjugates - Stock Titan
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes - ChartMill
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InfraRX Down Ahead of Next Quarterly Report - Baystreet.ca
IFRX - Finviz
InflaRx N.V. to Publish Q1 2026 Financial Results on May 7, 2026 - Quiver Quantitative
InflaRx to Report First Quarter 2026 Results on May 7, 2026 - ChartMill
InflaRx N.V. (NASDAQ:IFRX) Short Interest Update - MarketBeat
InflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status - The Globe and Mail
InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
InflaRx (Nasdaq: IFRX) back in line with Nasdaq minimum bid price rule - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Nasdaq closes InflaRx listing issue after stock holds above $1 - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance - Investing.com
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM - The Globe and Mail
InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer - MarketBeat
Oppenheimer Adjusts Price Target on InflaRx to $5 From $7, Maintains Outperform Rating - marketscreener.com
InflaRx receives Nasdaq notification - MSN
1.77%
0.25%
자본화:
|
볼륨(24시간):